AI In Regulatory Information Management - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The aI in regulatory information management market size is projected to expand from USD 0.95 billion in 2025 and USD 1.13 billion in 2026 to USD 2.62 billion by 2031, registering a CAGR of 18.35% between 2026 to 2031. This report is Segmented by Component (Software Platforms and Services), Deployment Mode (Cloud-Based, On-Premises, and Hybrid), AI Capability (Natural Language Processing and Document Intelligence, and More), Application (Regulatory Intelligence, and More), End User (Pharmaceutical Companies, and More), and Geography (North America, Europe, and More). Forecasts are in Value (USD).

Global AI In Regulatory Information Management Market Trends and Insights

Rising Submission and Variation Volumes: A Scale Problem Beyond Manual Capacity

The AI in regulatory information management market is being driven by a workload curve that manual teams cannot absorb at current filing volumes. The FDA approved 143 NDAs and BLAs in fiscal 2025, and FAERS received more than 20 million adverse event reports in 2024, which shows how sharply regulated content volumes have expanded. Each approval also creates follow-on variations, renewals, labeling updates, and commitment tracking work, so the regulatory burden extends well beyond the first submission milestone. Large pharmaceutical teams already manage hundreds of submissions each month, which makes scale, speed, and internal consistency more difficult to maintain with manual methods alone. This is pushing regulatory groups to shift effort away from repetitive document production and toward scientific judgment, review strategy, and issue resolution. The result is recurring demand for AI-enabled RIM tools because the workload driver is structural and not limited to one temporary automation cycle.

Pressure to Shorten Dossier Cycle Times: Competitive Windows Measured in Weeks

The AI in regulatory information management market is also benefiting from stronger pressure to shorten drafting, review, and publishing timelines. Review windows are commercially important, so companies want earlier draft completion, cleaner cross-functional coordination, and fewer late-stage rework cycles. IBM said its Regulate.AI platform reduced regulatory writer time by 50% to 60%, while Yseop and Indegene both advanced automation roadmaps aimed at faster medical writing and dossier preparation. Faster authoring also improves quality because teams can spend more time reviewing scientific logic and less time repairing inconsistencies across modules. That matters because inconsistencies across sections often trigger questions, information requests, and avoidable review friction. Vendors that combine authoring, version control, reuse, and publishing inside a validated workflow are therefore gaining stronger attention than stand-alone drafting tools.

GxP Validation and AI Governance Burden: A Compliance Architecture Mismatch

The AI in regulatory information management market still faces a governance burden because many validation models were built for deterministic software and not for probabilistic AI outputs. The FDA’s January 2025 draft guidance introduced a seven-step credibility framework for AI used to support regulatory decision-making for drugs and biological products, which increases evidence, testing, and documentation expectations. EMA’s reflection paper on AI in the medicinal product lifecycle also makes clear that AI use needs risk-based controls, human oversight, traceability, and a documented lifecycle approach. These requirements slow implementation in quality-critical workflows because companies must validate both the system and the role of its outputs in regulated decisions. That doubles governance work for many use cases and raises the bar for new entrants that lack established compliance processes. The burden does not stop adoption, but it does favor vendors that can offer locked models, audit trails, and inspection-ready evidence packages.

Other drivers and restraints analyzed in the detailed report include:

• eCTD 4.0 and IDMP Structured-data Readiness: Infrastructure for the AI-Native Submission Era
• Continuous Regulatory Intelligence Automation: From Reactive Monitoring to Proactive Risk Management
• Fragmented Global Data Standards: An Obstacle Embedded in Foundational Infrastructure

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Software Platforms held 45.16% of the AI in regulatory information management market share in 2025, while Services is projected to expand at 20.88% CAGR through 2031. Platform demand remained strongest among large biopharma companies that had already centralized submission, registration, and intelligence workflows on cloud RIM suites. Veeva said more than 450 companies, including 19 of the top 20 global biopharma firms, operated on its RIM platform in 2025, which shows how deeply unified enterprise platforms are already embedded in the top tier. That depth of adoption gives software vendors a strong installed base, but it also means the largest accounts are less open to net-new license displacement than they were earlier in the digitization cycle. As a result, the software layer remains strategically central in the AI in regulatory information management market, but its growth now depends more on added capability depth than on pure seat expansion.

Services are growing faster because many companies still need outside support to make those platforms work at enterprise scale. GxP-ready implementation, migration design, validation, taxonomy cleanup, and operating model redesign all require skills that many regulatory teams do not hold internally. Mid-sized biopharma companies and emerging sponsors also rely on service partners for publishing, dossier preparation, and regulatory intelligence operations when internal teams are lean. This makes value realization a bigger spending priority than software ownership alone, especially after the initial platform decision has already been made. In the AI in regulatory information management industry, this keeps services as the clearest growth outlet because enterprise demand is shifting from platform acquisition toward platform activation and sustained usage.

Cloud-based deployment accounted for 38.17% of the AI in regulatory information management market size by deployment in 2025, while on-premises deployment is projected to grow at 19.12% CAGR through 2031. Cloud remained the largest model because it supports unified workflows, easier updates, and stronger reuse across submission management, intelligence, and collaboration tasks. EMA’s Scientific Explorer data protection notice stated in March 2026 that processing takes place within EU-region Azure servers and that EMA data is not stored or used to retrain AI models, which reflects the type of documented cloud controls that regulated users now expect. That kind of operating model supports cloud adoption because it shows that region-specific processing controls can be built into AI-enabled regulatory environments. The cloud lead in the AI in regulatory information management market therefore remains intact, especially for multinational organizations that want shared workflows across business units and countries.

The faster growth of on-premises deployment looks counterintuitive at first, but it aligns with data residency, sovereignty, and cross-border transfer concerns in several jurisdictions. Companies filing across China, India, parts of the Middle East, and other sensitive markets often need tighter local control over submission-related product information and supporting records. Hybrid architecture is therefore becoming the practical middle ground because it allows central workflow orchestration while keeping some regulated data stores under local control. This makes deployment mode a regulatory design choice and not just an IT preference, especially for global companies that must satisfy conflicting national requirements. The same pattern also helps explain why the AI in regulatory information management market continues to support multiple deployment models rather than converging quickly toward a single standard.

Complete Report Scope:

• By Component
  • Software Platforms
  • Services
• By Deployment Mode
  • Cloud-based
  • On-premises
  • Hybrid
• By AI Capability
  • Natural language processing and document intelligence
  • Generative AI authoring and summarization
  • Regulatory knowledge graph and semantic search
  • Predictive analytics and risk scoring
  • Workflow orchestration and agentic automation
• By Application
  • Regulatory intelligence
  • Dossier authoring and content assembly
  • Regulatory submissions and publishing
  • Product registration and approvals
  • Labeling and artwork change management
  • Health authority interactions and commitments management
  • Data migration and master data stewardship
  • Pharmacovigilance and safety reporting
• By End User
  • Pharmaceutical companies
  • Biotechnology companies
  • Medical device and diagnostics companies
  • Other End Users
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America accounted for 39.18% of the AI in regulatory information management market share in 2025. The region led because it combined the FDA’s mature eCTD ecosystem, tight review timelines, and the world’s deepest concentration of large pharmaceutical and biotech R&D operations. The FDA’s January 2025 draft guidance on AI credibility in drug and biological product submissions also gave the market a clearer regulatory framework, which supports more structured vendor and sponsor investment. North America also has a dense vendor base that includes Veeva, IQVIA, Clarivate, Indegene, and multiple AI-native startups, which shortens product feedback loops and supports faster feature development. This combination of regulatory formality, enterprise buying power, and vendor proximity keeps North America central to the AI in regulatory information management market even as other regions accelerate.

Europe is one of the most mandate-driven regional blocks in the AI in regulatory information management market. EMA completed its cloud migration in 2024, adopted the NDSG 2026 to 2028 workplan in early 2026, and launched the AI-enabled Scientific Explorer tool to national competent authorities in March 2026, which shows active institutional participation in AI adoption. The region also concentrates structured-data work because marketing authorization holders must improve product data quality and governance to support broader digital regulatory operations. Germany, France, and the United Kingdom lead adoption because they combine major pharma R&D activity with strong engineering and service talent around regulatory systems. Italy and Spain add secondary growth potential as manufacturing, pharmacovigilance, and lifecycle management obligations continue to widen the need for digital regulatory control.

Asia-Pacific is projected to expand at 19.36% CAGR through 2031, making it the fastest-growing regional outlook within the AI in regulatory information management market size by geography. PMDA published its AI utilization action plan in October 2025, began using generative AI in operations from April 2026, and made eCTD 4.0 mandatory for new drug applications from the same month, which signals synchronized modernization in Japan. China’s 2026 implementation opinions and the NMPA Information Centre’s work on large language models in drug regulation show that institutional AI readiness is moving beyond policy language into operational systems. South Korea and Australia remain smaller but established markets, while South America and the Middle East and Africa are still earlier-stage markets that are usually served through services-led support for multinational registration portfolios.

List of Companies Covered in this Report:

• AmpleLogic
• Aris Global
• Celegence
• Clarivate
• DnXT Solutions
• Ennov
• Essenvia
• EXTEDO
• FREYR / Freya Fusion
• Generis
• Indegene
• IQVIA
• LORENZ Life Sciences
• MasterControl
• Navitas Life Sciences
• Parexel International
• RegDesk
• Rimsys
• Veeva Systems

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support